Antibody and T Cell Responses against SARS-CoV-2 Elicited by the Third Dose of BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) Vaccines Using a Homologous or Heterologous Booster Vaccination Strategy

In the present study, antibody and T cell-mediated immune responses elicited by BBIBP-CorV and BNT162b2 vaccines were compared 6 months after the two-dose immunization of healthy individuals. Additionally, antibody and T cell responses after the third dose of BBIBP-CorV or BNT162b2 were compared usi...

Descripción completa

Detalles Bibliográficos
Autores principales: Matula, Zsolt, Gönczi, Márton, Bekő, Gabriella, Kádár, Béla, Ajzner, Éva, Uher, Ferenc, Vályi-Nagy, István
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025723/
https://www.ncbi.nlm.nih.gov/pubmed/35455288
http://dx.doi.org/10.3390/vaccines10040539

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025723/
https://www.ncbi.nlm.nih.gov/pubmed/35455288
http://dx.doi.org/10.3390/vaccines10040539

Ejemplares similares